@article{8a07a95db3b24de58484293b49c0ed43,
title = "COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave",
abstract = "Purpose of Review: To review the current evidence regarding the impact of the coronavirus disease 2019 (COVID-19) pandemic on cardiometabolic health, with a focus on strategies to help mitigate adverse effects on population health. Recent Findings: Individuals with cardiometabolic disease are particularly vulnerable to worse outcomes with COVID-19 infection. In addition, the pandemic itself has had significant deleterious impact on the cardiometabolic health of the population, including declines in physical activity, increases in smoking and alcohol use, worsening blood pressure and glycemic control, and detrimental effects on mental health. Targeted interventions at the patient and community level will be needed to mitigate the long-term consequences of the COVID-19 pandemic on population cardiometabolic health. Summary: The COVID-19 pandemic has worsened cardiometabolic health, but there are several opportunities and enhanced tools available to counteract these changes.",
keywords = "COVID-19, Cardiometabolic health, Obesity",
author = "Kolkailah, {Ahmed A.} and Kayla Riggs and Navar, {Ann Marie} and Amit Khera",
note = "Funding Information: Dr. Navar reports grant support from BMS, Esperion, and Janssen; and consulting for Amarin, Amgen, AstraZeneca, BI, Bayer, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, NovoNordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 80Bio, and Pfizer. Dr. Navar also reports leadership or fiduciary role in the American Society for Preventive Cardiology, the National Forum, and JAMA Cardiology. Dr. Khera reports leadership or fiduciary role in the American Society for Preventive Cardiology Board. The other authors declare that they have no conflict of interest. Funding Information: Dr. Kolkailah was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL125247. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2022",
month = aug,
doi = "10.1007/s11883-022-01033-7",
language = "English (US)",
volume = "24",
pages = "607--617",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "8",
}